What is it about?
In growth hormone deficient subjects insulin-like growth factor-I Z-scores significantly differed when two different normative data sets produced for the IDS-iSYS insulin-like growth factor-I assay were compared both at baseline and during long-term treatment with growth hormone.
Featured Image
Why is it important?
In daily clinical practice, this would most likely have led to different clinical interpretations and growth hormone dose adjustments in this study population.
Perspectives
We suggest that disagreements in normative insulin-like growth factor-I values calculated in different studies may be due not only to differences in the population samples and analytical variability of an insulin-like growth factor-I assay, but also directly to (weaknesses of) the statistical methods used to produce these insulin-like growth factor-I normative data.
JAMJL Janssen
Erasmus Universiteit Rotterdam
Read the Original
This page is a summary of: Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency, Clinical Endocrinology, October 2017, Wiley,
DOI: 10.1111/cen.13491.
You can read the full text:
Contributors
The following have contributed to this page
